v3.25.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2023 $ 18,625 $ 42 $ 129,763 $ (150,741) $ (2,311)
Balance, shares at Dec. 31, 2023 18,625 42,329,864      
Balance at Mar. 31, 2024 $ 44,285 $ 47 136,411 (168,849) 11,894
Balance, shares at Mar. 31, 2024 44,285 46,747,062      
Balance at Dec. 31, 2023 $ 18,625 $ 42 129,763 (150,741) (2,311)
Balance, shares at Dec. 31, 2023 18,625 42,329,864      
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan 4 4
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares   3,333      
Stock-based compensation - Lucid Diagnostics Inc. 1,850 1,850
Stock-based compensation - PAVmed Inc. 285 285
Issuance - At-The-Market Facility, net of financing charges
Net loss (21,617) (21,617)
Purchase - Employee Stock Purchase Plan $ 1 352 353
Purchase - Employee Stock Purchase Plan, shares   511,884      
Conversions - Senior Secured Convertible Note $ 3 2,538 2,541
Conversions - Senior Secured Convertible Note, shares   2,661,181      
Issue common stock - vendor service agreement 401 401
Issue common stock - vendor service agreement, shares   480,000      
Vest - restricted stock awards
Vest - restricted stock awards, shares   26,912      
Issuance - Series A-1 Preferred Stock $ 5,670 5,670
Issuance - Series A-1 Preferred Stock, shares 5,670        
Exchange - Series A and Series A-1 Preferred Stock $ (24,295) (7,496) (31,791)
Exchange - Series A and Series A-1 Preferred Stock, shares (24,295)        
Issuance through exchange - Series B Preferred Stock $ 31,790 31,790
Issuance through exchange - Series B and Series B-1 Preferred Stock, shares 31,790        
Issuance through sale- Series B and Series B-1 Preferred Stock $ 24,129 24,129
Issuance through sale- Series B and Series B-1 Preferred Stock, shares 24,129        
Issuance - Due To: PAVmed Inc. Settlement in Common Stock $ 3 4,672 4,675
Issuance - Due To: PAVmed Inc. Settlement in Common Stock, shares   3,331,771      
Balance at Jun. 30, 2024 $ 55,919 $ 49 139,865 (179,854) 15,979
Balance, shares at Jun. 30, 2024 55,919 49,344,945      
Balance at Mar. 31, 2024 $ 44,285 $ 47 136,411 (168,849) 11,894
Balance, shares at Mar. 31, 2024 44,285 46,747,062      
Stock-based compensation - Lucid Diagnostics Inc. 1,106 1,106
Stock-based compensation - PAVmed Inc. 95 95
Net loss (11,005) (11,005)
Conversions - Senior Secured Convertible Note $ 2 1,852 1,854
Conversions - Senior Secured Convertible Note, shares   2,117,883      
Issuance through sale - Series B-1 Preferred Stock $ 11,634,000 11,634
Issuance through sale - Series B-1 Preferred Stock, shares 11,634        
Issue common stock - vendor service agreement 401 401
Issue common stock - vendor service agreement, shares   480,000      
Balance at Jun. 30, 2024 $ 55,919 $ 49 139,865 (179,854) 15,979
Balance, shares at Jun. 30, 2024 55,919 49,344,945      
Balance at Dec. 31, 2024 $ 54,419 $ 63 154,675 (203,766) 5,391
Balance, shares at Dec. 31, 2024 54,419 63,071,950      
Balance at Mar. 31, 2025 $ 54,419 $ 84 179,904 (239,784) (5,377)
Balance, shares at Mar. 31, 2025 54,419 84,374,455      
Balance at Dec. 31, 2024 $ 54,419 $ 63 154,675 (203,766) 5,391
Balance, shares at Dec. 31, 2024 54,419 63,071,950      
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan 13 $ 13
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares   10,891     10,891
Stock-based compensation - Lucid Diagnostics Inc. 2,092 $ 2,092
Stock-based compensation - PAVmed Inc. 82 82
Issuance - At-The-Market Facility, net of financing charges 274 274
Issuance - At-The-Market Facility, net of deferred financing charges, shares   215,421      
Issuance - Interest payment paid in stock $ 1 106 107
Issuance - Interest payment paid in stock, shares   89,722      
Issuance - Confidentially Marketed Public Offering, net of fees $ 14 16,160 16,174
Issuance - Confidentially Marketed Public Offering, net of fees, shares   14,375,000      
Issuance - Dividend on Series B and Series B-1 Preferred Stock $ 10 12,549 (12,559)
Issuance - Dividend on Series B and Series B-1 Preferred Stock, shares   9,921,423      
Net loss (31,347) (31,347)
Purchase - Employee Stock Purchase Plan 141 141
Purchase - Employee Stock Purchase Plan, shares   203,051      
Issuance - Registered Direct Offering, net of fees $ 14 14,921 14,935
Issuance - Registered Direct Offering, net of fees, shares   13,939,330      
Balance at Jun. 30, 2025 $ 54,419 $ 102 201,013 (247,672) 7,862
Balance, shares at Jun. 30, 2025 54,419 101,826,788      
Balance at Mar. 31, 2025 $ 54,419 $ 84 179,904 (239,784) (5,377)
Balance, shares at Mar. 31, 2025 54,419 84,374,455      
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan 11 11
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares   8,998      
Stock-based compensation - Lucid Diagnostics Inc. 1,142 1,142
Stock-based compensation - PAVmed Inc. 1 1
Issuance - At-The-Market Facility, net of financing charges 274 274
Issuance - At-The-Market Facility, net of deferred financing charges, shares   215,421      
Issuance - Interest payment paid in stock $ 1 75 76
Issuance - Interest payment paid in stock, shares   48,954      
Issuance - Confidentially Marketed Public Offering, net of fees $ 14 16,160 16,174
Issuance - Confidentially Marketed Public Offering, net of fees, shares   14,375,000      
Issuance - Dividend on Series B and Series B-1 Preferred Stock $ 3 3,446 (3,449)
Issuance - Dividend on Series B and Series B-1 Preferred Stock, shares   2,803,960      
Net loss (4,439) (4,439)
Balance at Jun. 30, 2025 $ 54,419 $ 102 $ 201,013 $ (247,672) $ 7,862
Balance, shares at Jun. 30, 2025 54,419 101,826,788